<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00033423</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069282</org_study_id>
    <secondary_id>UAB-0127</secondary_id>
    <secondary_id>UAB-F010806018</secondary_id>
    <secondary_id>NCI-G02-2053</secondary_id>
    <nct_id>NCT00033423</nct_id>
  </id_info>
  <brief_title>Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase I, Multicenter, Open Label, Dose Escalation Of 90Y-Zevalin Radioimmunotherapy Using A Modified Treatment Regimen For Relapsed Or Refractory CD20+ B-Cell (Follicular/Transformed) Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody in&#xD;
      treating patients who have relapsed or refractory non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of yttrium Y 90 ibritumomab tiuxetan when&#xD;
           administered in combination with rituximab in patients with relapsed or refractory&#xD;
           low-grade, follicular, or transformed CD20-positive B-cell non-Hodgkin's lymphoma (NHL).&#xD;
&#xD;
        -  Determine the toxicity of different doses of yttrium Y 90 ibritumomab tiuxetan in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the frequency of reversal of bone marrow involvement with NHL in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the antitumor response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of yttrium Y 90 ibritumomab tiuxetan.&#xD;
&#xD;
      Patients receive rituximab IV once weekly on weeks 1-4. After 4 doses of rituximab, patients&#xD;
      without bone marrow involvement and cellularity greater than 50% expected receive rituximab&#xD;
      IV once weekly on weeks 6 and 7 and yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes with&#xD;
      the final dose of rituximab (day 43).&#xD;
&#xD;
      Cohorts of 5-6 patients receive escalating dose of yttrium Y 90 ibritumomab tiuxetan until&#xD;
      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that&#xD;
      at which 4 of 5 or 3 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 6 and 12 weeks, every 2-3 months for 2 years, and then every 6&#xD;
      months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 6-30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose of yttrium Y 90 ibritumomab tiuxetan when administered in combination with rituximab in patients with relapsed or refractory low-grade, follicular, or transformed CD20-positive B-cell non-Hodgkin's lymphoma (NHL).</measure>
    <time_frame>baseline through 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the toxicity of different doses of yttrium Y 90 ibritumomab tiuxetan in patients treated with this regimen</measure>
    <time_frame>baseline through 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the frequency of reversal of bone marrow involvement with NHL in patients treated with this regimen.</measure>
    <time_frame>baseline through 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the antitumor response in patients treated with this regimen.</measure>
    <time_frame>baseline through 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Third radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fourth radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTD radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort II</arm_group_label>
    <arm_group_label>Cohort III</arm_group_label>
    <arm_group_label>Cohort IV</arm_group_label>
    <arm_group_label>Cohort V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 ibritumomab tiuxetan</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort II</arm_group_label>
    <arm_group_label>Cohort III</arm_group_label>
    <arm_group_label>Cohort IV</arm_group_label>
    <arm_group_label>Cohort V</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed low-grade, follicular, or transformed CD20-positive B-cell&#xD;
             non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
          -  Relapsed after prior chemotherapy OR chemotherapy-resistant disease&#xD;
&#xD;
          -  Failed at least 1 prior chemotherapy regimen&#xD;
&#xD;
          -  CD20-positive B-cell population in lymph nodes or bone marrow for International&#xD;
             Working Formulation A (small lymphocytic lymphoma) and transformed NHL&#xD;
&#xD;
          -  Bone marrow involvement with lymphoma less than 25% bilaterally&#xD;
&#xD;
          -  No impaired bone marrow reserve defined as at least 1 of the following criteria:&#xD;
&#xD;
               -  Prior myeloablative therapies with bone marrow transplantation or peripheral&#xD;
                  blood stem cell rescue&#xD;
&#xD;
               -  Platelet count less than 100,000/mm3&#xD;
&#xD;
               -  Bone marrow cellularity no greater than 15%&#xD;
&#xD;
               -  Marked reduction in bone marrow precursors of one or more cell lines (e.g.,&#xD;
                  granulocytic, megakaryocytic, or erythroid)&#xD;
&#xD;
               -  Failed prior stem cell collection&#xD;
&#xD;
          -  No CNS lymphoma, chronic lymphocytic lymphoma, or HIV or AIDS-related lymphoma&#xD;
&#xD;
          -  No diffuse small lymphocytic/marginal zone lymphoma with lymphocyte count greater than&#xD;
             5,000/mm^3&#xD;
&#xD;
          -  No pleural effusion NOTE: A new classification scheme for adult non-Hodgkin's lymphoma&#xD;
             has been adopted by PDQ. The terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will&#xD;
             replace the former terminology of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma.&#xD;
             However, this protocol uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  19 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hematocrit greater than 30%&#xD;
&#xD;
          -  Hemoglobin greater than 9.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
             participation&#xD;
&#xD;
          -  No anti-murine antibody reactivity if prior exposure to murine antibodies or proteins&#xD;
&#xD;
          -  No other primary malignancy&#xD;
&#xD;
          -  No other serious nonmalignant disease or infection that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radioimmunotherapy&#xD;
&#xD;
          -  Prior rituximab allowed if more than 6 months to progression after an objective&#xD;
             response&#xD;
&#xD;
          -  At least 6 weeks since prior rituximab&#xD;
&#xD;
          -  At least 3 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior fludarabine&#xD;
&#xD;
          -  At least 3 weeks since prior anticancer chemotherapy (6 weeks for nitrosoureas or&#xD;
             mitomycin) and recovered&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior anticancer endocrine therapy&#xD;
&#xD;
          -  No concurrent high-dose systemic corticosteroids (e.g., 50 mg or more of prednisone as&#xD;
             a single dose or 50 mg or less of prednisone for more than 6 doses)&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of active bone marrow (involved field or&#xD;
             regional)&#xD;
&#xD;
          -  At least 3 weeks since prior anticancer radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since prior surgery (except diagnostic surgery) and recovered&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  Concurrent oral anticoagulant therapy allowed if platelet count is at least 30,000/mm3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres Forero-Torres, MD, CSU</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Comprehensive Cancer Center - Stanford</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Forero-Torres A, Besh S, Knox S, et al.: Higher doses of Rituxan alter pharmacokinetics and biodistribution of Zevalin but may increase responses; a preliminary report of a phase I study of Zevalin using a modified treatment regimen for relapsed or refractory CD20+ B-Cell follicular/transformed non-Hodgkins lymphoma. [Abstract] Blood 102 (11 Pt 1): A-1483, 2003.</citation>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>April 9, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 12, 2013</last_update_submitted>
  <last_update_submitted_qc>December 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

